Econazole is an azole antifungal indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. MedsAcross supplies Econazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Econazole nitrate topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. Econazole nitrate is an azole antifungal indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.
Source: US FDA prescribing information
Econazole nitrate topical foam is an azole antifungal.
Source: US FDA prescribing information
Econazole nitrate topical foam, 1% is for topical use only. Econazole nitrate topical foam, 1% is not for oral, ophthalmic, or intravaginal use. Econazole nitrate topical foam, 1% should be applied to cover affected areas once daily for 4 weeks. For topical use only, not for oral, ophthalmic, or intravaginal use. Apply once daily for 4 weeks.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
- Contents are flammable. Instruct the patient to avoid heat, flame, and/or smoking during and immediately following application. Flammability Econazole nitrate topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty. Do not store in direct sunlight.
Source: US FDA prescribing information
- During clinical trials with econazole nitrate topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the econazole nitrate and vehicle arms. Revised: 09/2025
Source: US FDA prescribing information
- Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect. Most cases reported product application with use under occlusion, genital application, or application to a large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.
Source: US FDA prescribing information
Store at controlled room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). Do not refrigerate or freeze. Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty. Do not store in direct sunlight.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Econazole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Econazole 1% creamTopicalGeneric name | — | US FDA | Available on request |
| Econazole 1% foamTopicalGeneric name | — | US FDA | Available on request |
| Ecoza 1% foamTopical | Resilia Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 23 December 1982 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Econazole in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Econazole and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Econazole, including Ecoza.
Yes. The US FDA first approved Econazole on 23 December 1982, according to Drugs@FDA.
No listed presentation of Econazole is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Econazole is classified under ATC code D01AC03 (Econazole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.